ADAR1 Capital Management LLC Has $843,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

ADAR1 Capital Management LLC increased its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 62.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,505 shares of the company’s stock after purchasing an additional 7,505 shares during the period. ADAR1 Capital Management LLC’s holdings in Scholar Rock were worth $843,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRRK. GAMMA Investing LLC lifted its holdings in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. Quarry LP increased its holdings in Scholar Rock by 3,443.3% during the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after purchasing an additional 4,373 shares in the last quarter. Global Retirement Partners LLC increased its stake in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after buying an additional 1,031 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after acquiring an additional 620 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of SRRK stock opened at $26.90 on Monday. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -11.45 and a beta of 0.56. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average of $36.31 and a 200-day moving average of $34.01.

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $42.67.

Insiders Place Their Bets

In other news, CEO Jay T. Backstrom sold 22,308 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $986,013.60. Following the completion of the transaction, the chief executive officer now directly owns 330,363 shares in the company, valued at $14,602,044.60. This represents a 6.33 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 12,539 shares of Scholar Rock stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $554,223.80. Following the completion of the sale, the chief financial officer now directly owns 148,549 shares in the company, valued at approximately $6,565,865.80. This represents a 7.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock worth $11,245,798 over the last ninety days. 19.20% of the stock is currently owned by corporate insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.